Literature DB >> 19217515

Managing statin myopathy.

Carmelo V Venero1, Paul D Thompson.   

Abstract

Approximately 10% of patients treated with statins experience some form of muscle-related side effects in clinical practice. These can range from asymptomatic creatine kinase (CK) elevation, to muscle pain, weakness, and its most severe form, rhabdomyolysis. Higher risk patients for statin myopathy are those older than 80, with a small body frame, on higher statin doses, on other medications, or with other systemic diseases including hepatic or renal diseases, diabetes mellitus, or hypothyroidism. The cause of statin myopathy is presumed to be the same for its variable presentation but has not been defined. In patients with myopathic symptoms, their symptoms and CK levels determine whether statin therapy can be continued or must be stopped.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19217515     DOI: 10.1016/j.ecl.2008.11.002

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  14 in total

1.  Coenzyme Q(10) and statin myalgia: what is the evidence?

Authors:  Emilie Mas; Trevor A Mori
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

2.  Simvastatin represses protein synthesis in the muscle-derived C₂C₁₂ cell line with a concomitant reduction in eukaryotic initiation factor 2B expression.

Authors:  Alexander P Tuckow; Sarah J Jefferson; Scot R Kimball; Leonard S Jefferson
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-01-11       Impact factor: 4.310

Review 3.  Evidence-based management of statin myopathy.

Authors:  Charles R Harper; Terry A Jacobson
Journal:  Curr Atheroscler Rep       Date:  2010-09       Impact factor: 5.113

Review 4.  Do statins have a role in the prevention of age-related macular degeneration?

Authors:  Sean W Tsao; Donald S Fong
Journal:  Drugs Aging       Date:  2013-04       Impact factor: 3.923

5.  Influence of Baseline Psychological Health on Muscle Pain During Atorvastatin Treatment.

Authors:  Amanda L Zaleski; Beth A Taylor; Linda S Pescatello; Ellen A Dornelas; Charles Michael White; Paul D Thompson
Journal:  J Cardiovasc Nurs       Date:  2017 Nov/Dec       Impact factor: 2.083

Review 6.  Management of the patient with statin intolerance.

Authors:  Byron F Vandenberg; Jennifer Robinson
Journal:  Curr Atheroscler Rep       Date:  2010-01       Impact factor: 5.113

7.  L-Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized rats.

Authors:  Hussam A S Murad
Journal:  J Zhejiang Univ Sci B       Date:  2016-01       Impact factor: 3.066

8.  Geranylgeraniol-induced Myogenic Differentiation of C2C12 Cells.

Authors:  Takuma Matsubara; Mariko Urata; Tsuyoshi Nakajima; Mari Fukuzaki; Ryo Masuda; Yoshiyuki Yoshimoto; William N Addison; Chihiro Nakatomi; Kazmasa Morikawa; Min Zhang; Katsura Saeki; Yukiko Takahashi; Atsuko Nakamichi; Shoichiro Kokabu
Journal:  In Vivo       Date:  2018 Nov-Dec       Impact factor: 2.155

9.  Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway.

Authors:  Ira J Goldberg; Li-Shin Huang; Lesley A Huggins; Shuiqing Yu; Prabhakara R Nagareddy; Thomas S Scanlan; Joel R Ehrenkranz
Journal:  Endocrinology       Date:  2012-09-04       Impact factor: 4.736

10.  Protection of rat skeletal muscle fibers by either L-carnitine or coenzyme Q10 against statins toxicity mediated by mitochondrial reactive oxygen generation.

Authors:  P G La Guardia; L C Alberici; F G Ravagnani; R R Catharino; A E Vercesi
Journal:  Front Physiol       Date:  2013-05-15       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.